A recent New York Times investigation also found that many officers who come to work…
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) experienced a sharp drop in short-term interest during the month of March. As of March 15, there was short interest totaling 349,600 shares, a decline of 49.0% from February 28’s total of 685,800 shares. Based on an average trading volume of 477,900 shares, the short-term interest rate ratio is currently 0.7 days.
Several hedge funds and other institutional investors have recently changed their positions in the company. Pzena Investment Management LLC purchased a new equity position in Fresenius Medical Care AG & Co. KGaA in the third quarter, valued at approximately $224,080,000. Arrowstreet Capital Limited Partnership acquired a new equity stake in Fresenius Medical Care AG & Co. KGaA in the third quarter valued at approximately $6,977,000. Whittier Trust Co. of Nevada Inc. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 98.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 1,733 shares of the company valued at $61,000 after buying 859 additional shares in the last quarter. BOKF NA bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the third quarter for a value of approximately $934,000. Finally, Cacti Asset Management LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth approximately $860,000. Institutional investors and hedge funds hold 4.89% of the company’s shares.
FMS stock traded at $0.41 midday on Monday, hitting $33.61. 790,447 shares of the company were traded, against an average volume of 528,459. The company has a debt ratio of 0.48, a current ratio of 1.10 and a quick ratio of 0.82. Fresenius Medical Care AG & Co. KGaA has a 12 month minimum of $28.75 and a 12 month maximum of $42.45. The stock’s 50-day moving average is $32.90 and its 200-day moving average is $33.18. The company has a market capitalization of $19.70 billion, a price-to-earnings ratio of 16.94, a growth price-to-earnings ratio of 1.50 and a beta of 1.19.
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) last announced its results on Tuesday, February 22. The company reported earnings per share (EPS) of $0.51 for the quarter, beating consensus analyst estimates of $0.50 by $0.01. The company posted revenue of $5.31 billion for the quarter, versus analyst estimates of $5.38 billion. Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 7.51% and a net margin of 5.51%. On average, research analysts expect Fresenius Medical Care AG & Co. KGaA to post earnings per share of 2.08 for the current fiscal year.
FMS has been the subject of a number of research reports. Zacks Investment Research upgraded Fresenius Medical Care AG & Co. KGaA from a “Strong Sell” rating to a “Hold” rating and set a target price of $35.00 for the company in a Tuesday, January 11 report. Berenberg Bank lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €84.90 ($93.30) to €83.40 ($91.65) in a Thursday, March 17 report. Oddo Bhf has upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperforming” rating and has set a price target of €72.00 ($79.12) on the share in a research note from Tuesday, March 1. StockNews.com moved shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “buy” rating in a Tuesday, March 1, report. Finally, Societe Generale reduced its price target on Fresenius Medical Care AG & Co. KGaA from €61.00 ($67.03) to €57.00 ($62.64) in a Friday, February 25 research report. . Two analysts have assigned the stock a sell rating, eight have assigned a hold rating and six have assigned the stock a buy rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $51.71.
About Fresenius Medical Care AG & Co. KGaA (Get a rating)
Fresenius Medical Care AG & Co KgaA provides products and services for people with kidney disease. The company develops and manufactures healthcare products, including dialysis and non-dialysis products. It operates through the following segments: North America segment; EMEA Segment; Asia-Pacific segment; and Latin America segment.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Fresenius Medical Care AG & Co. KGaA right now?
Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.
While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here